The first European multi-stakeholder model to address biomarker based drug development and promote innovative partnership successfully gathered in Brussels on 07 November 2013.  The meeting convened circa 80 selected representatives of patient groups, academic researchers, regulators, government, European Union commission, pharmaceutical industry sector, and diagnostic and technology companies alongside EORTC officers and representatives.

The EORTC has announced that it will build a Screening Program for Efficient Clinical Trial Access for patients with lung cancer. This program, SPECTAlung, will prospectively collect biological materials from patients who have been diagnosed with lung cancer, starting with non-small cell lung cancer (NSCLC) and enable efficient clinical trial access for these patients.

Thursday 7 March 2013

Opening remarks & Positioning the EORTC in the changing clinical research landscape - R. Stupp

EORTC trial 18081

Adjuvant peginterferon alpha-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group

Target Accrual: 1200 patients
Study Coordinator:
    Alessandro Testori - Istituto Europeo Di Oncologia, Milano